Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast cancer
KE Roberts, IT Adsett, K Rickett… - Cochrane Database …, 2022 - cochranelibrary.com
Background Adjuvant aromatase inhibitors (AI) improve survival compared to tamoxifen in
postmenopausal women with hormone receptor‐positive stage I to III breast cancer. In …
postmenopausal women with hormone receptor‐positive stage I to III breast cancer. In …
[引用][C] Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast cancer
Cochrane Breast Cancer Group… - Cochrane Database …, 1996 - cochranelibrary.com
Background Adjuvant aromatase inhibitors (AI) improve survival compared to tamoxifen in
postmenopausal women with hormone receptor‐positive stage I to III breast cancer. In …
postmenopausal women with hormone receptor‐positive stage I to III breast cancer. In …
[HTML][HTML] Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast cancer
KE Roberts, IT Adsett, K Rickett… - The Cochrane …, 2022 - ncbi.nlm.nih.gov
Background Adjuvant aromatase inhibitors (AI) improve survival compared to tamoxifen in
postmenopausal women with hormone receptor‐positive stage I to III breast cancer. In …
postmenopausal women with hormone receptor‐positive stage I to III breast cancer. In …
[引用][C] Systemic therapies for preventing or treating aromatase inhibitor-induced musculoskeletal symptoms in early breast cancer
KE Roberts, K Rickett, MD Chatfield… - Cochrane Database …, 2018 - espace.library.uq.edu.au
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: To
assess the effects of systemic therapies on the prevention or management of AIMSS in …
assess the effects of systemic therapies on the prevention or management of AIMSS in …
Systemic therapies for preventing or treating aromatase inhibitor-induced musculoskeletal symptoms in early breast cancer.
KE Roberts, IT Adsett, K Rickett, SM Conroy… - The Cochrane …, 2022 - europepmc.org
Background Adjuvant aromatase inhibitors (AI) improve survival compared to tamoxifen in
postmenopausal women with hormone receptor-positive stage I to III breast cancer. In …
postmenopausal women with hormone receptor-positive stage I to III breast cancer. In …
Systemic therapies for preventing or treating aromatase inhibitor-induced musculoskeletal symptoms in early breast cancer
KE Roberts, IT Adsett, K Rickett… - The Cochrane …, 2022 - pubmed.ncbi.nlm.nih.gov
Background Adjuvant aromatase inhibitors (AI) improve survival compared to tamoxifen in
postmenopausal women with hormone receptor-positive stage I to III breast cancer. In …
postmenopausal women with hormone receptor-positive stage I to III breast cancer. In …
Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast cancer
K Roberts, K Rickett, M Chatfield… - The Cochrane Database …, 2018 - europepmc.org
Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal
symptoms in early breast cancer - Abstract - Europe PMC Sign in | Create an account https://orcid.org …
symptoms in early breast cancer - Abstract - Europe PMC Sign in | Create an account https://orcid.org …
[引用][C] Systemic therapies for preventing or treating aromatase inhibitor-induced musculoskeletal symptoms in early breast cancer
KE Roberts, IT Adsett, K Rickett… - Cochrane …, 2022 - espace.library.uq.edu.au
Background: Adjuvant aromatase inhibitors (AI) improve survival compared to tamoxifen in
postmenopausal women with hormone receptor-positive stage I to III breast cancer. In …
postmenopausal women with hormone receptor-positive stage I to III breast cancer. In …
[HTML][HTML] Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast cancer
KE Roberts, K Rickett, MD Chatfield… - … Cochrane Database of …, 2018 - ncbi.nlm.nih.gov
Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal
symptoms in early breast cancer - PMC Back to Top Skip to main content NIH NLM Logo …
symptoms in early breast cancer - PMC Back to Top Skip to main content NIH NLM Logo …